Health Care [ 8/12 ] | Biotechnology [ 57/74 ]
NYSE | Common Stock
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.
It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF PartnersL. P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer.
Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 26 | -1.02 Increased by +10.53% | -0.83 Decreased by -22.89% |
| Feb 25, 26 | -0.89 Increased by +13.59% | -1.10 Increased by +19.09% |
| Oct 28, 25 | -1.27 Decreased by -27.00% | -1.33 Increased by +4.51% |
| Aug 6, 25 | 0.00 Increased by +100.00% | -1.17 Increased by +100.00% |
| May 6, 25 | -1.14 Decreased by -700.00% | -1.08 Decreased by -5.56% |
| Feb 19, 25 | -1.03 Increased by +4.63% | -1.20 Increased by +14.39% |
| Nov 6, 24 | -1.00 Decreased by -6.38% | -1.07 Increased by +6.54% |
| Aug 8, 24 | -1.02 Increased by +1.92% | -1.39 Increased by +26.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 17.00 M Decreased by -39.29% | -128.00 M Decreased by -14.29% | Decreased by -752.94% Decreased by -88.24% |
| Dec 31, 25 | 33.00 M Increased by +26.92% | -98.00 M Decreased by -4.26% | Decreased by -296.97% Increased by +17.86% |
| Sep 30, 25 | 26.00 M Decreased by -45.83% | -135.00 M Decreased by -46.74% | Decreased by -519.23% Decreased by -170.90% |
| Jun 30, 25 | 160.00 M Increased by +310.26% | -8.00 M Increased by +91.40% | Decreased by -5.00% Increased by +97.90% |
| Mar 31, 25 | 28.00 M Decreased by -80.69% | -112.00 M Decreased by -2.70 K% | Decreased by -400.00% Decreased by -14.40 K% |
| Dec 31, 24 | 26.00 M Decreased by -16.13% | -94.00 M Decreased by -16.05% | Decreased by -361.54% Decreased by -38.37% |
| Sep 30, 24 | 48.00 M Increased by +50.00% | -92.00 M Decreased by -29.58% | Decreased by -191.67% Increased by +13.62% |
| Jun 30, 24 | 39.00 M Increased by +34.48% | -93.00 M Decreased by -24.00% | Decreased by -238.46% Increased by +7.79% |